ANVS Annovis Bio shares drop 387 after Q4 2025 wider loss misses analyst estimates by 114 Regeneron Pharmaceuticals REGN Otarmeni Gene Therapy Launch Shifts LongTerm Narrative Amid Pipeline Execution Focus GDDY GoDaddy notches 118 percent Q4 2025 EPS beat shares rise 15 percent in regular trading